How Old Drugs Could Steer a Fiery Cell-Death Pathway in Cancer — New Review Maps the Options
A new review explains pyroptosis — an inflammatory cell death executed by gasdermin proteins — and weighs repurposed drugs like disulfiram as ways to control it in cancer.
By Sanare Lab · October 3, 2026 · 2 min read
Key Takeaway
When a cell dies by pyroptosis — a fiery form of self-destruction that alerts the immune system — proteins called gasdermins punch the fatal holes in its membrane. A new review maps this family and the drugs that can control it, including disulfiram, an old alcohol-aversion pill. In cancer the pathway cuts both ways; the paper maps existing research, not new experiments.
Pyroptosis ends with the cell membrane rupturing and spilling pro-inflammatory cytokines — signaling molecules like IL-1β and IL-18 that rally immune cells to the scene. The review details how gasdermins are activated, form pores and cause rupture, and how this death mode crosstalks with others (apoptosis, necroptosis, PANoptosis — other cell-suicide routes).
Outside cell death, gasdermins act in mucus secretion, bone resorption and mitochondrial metabolism; in disease they are double-edged: defending against infections, driving chronic inflammation in autoimmune disorders, and playing context-dependent roles in cancer and immunity. The authors evaluate small-molecule inhibitors — disulfiram (DSF), necrosulfonamide and dimethyl fumarate — plus material-based delivery systems.
Honest framing: this review synthesizes published studies — no new patients, mice or numbers of its own; its value is the map. For related reading, see a new trial testing disulfiram with copper in thoracic cancer and pyroptosis triggered by another repurposed drug, fenbendazole; for dosing questions, our dosing calculator.
In plain words
What happened: Scientists published a big review — a summary of existing research — on gasdermins, proteins that execute a fiery, immune-alerting cell death called pyroptosis, and on drugs that control them.
Why it matters: This death pathway is like a burglar alarm: useful when it attracts immune cells to a tumor, harmful when it fuels chronic inflammation. Old drugs — including disulfiram, the alcohol-aversion pill — can turn it up or down, hence the need for a map.
How strong is the evidence: A review, not an experiment: it organizes what hundreds of labs already found. Reliable as a map, but it reports no new patients or results itself.
What it means for you: Nothing changes today — this is background science, not a new therapy. Do not take disulfiram or any drug outside medical care; ask your oncology team about trials if interested.
References
- Xu W, Liu S, Yu Z, et al. The gasdermin family: from pyroptosis mechanisms to therapeutic targets (a review — a synthesis of existing research). Signal Transduction and Targeted Therapy. 2026 Oct 2. doi:10.1038/s41392-026-02867-2. PMID: 42823398.
Medical Disclaimer
This article is for informational purposes only and is not medical advice. The paper is a review of existing research and reports no new clinical results. Never start, stop or change any medication without consulting a licensed healthcare provider.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.